Drug Type Autologous CAR-T |
Synonyms S 103, S-103(Hebei Senlangbio Biotechnology ), S103 + [2] |
Target |
Action modulators |
Mechanism BCMA modulators(B-cell maturation protein modulators), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Phase 1 | China | 21 Aug 2023 | |
Myasthenia Gravis | Clinical | China | - | |
Systemic Lupus Erythematosus | Clinical | China | - | |
Refractory Multiple Myeloma | IND Approval | China | 19 Mar 2025 | |
Relapse multiple myeloma | IND Approval | China | 19 Mar 2025 |